American Association for Cancer Research
10780432ccr170676-sup-180157_3_supp_4280496_hwjr7b.ppt (20.79 MB)

Supplementary Figures 1-9 from Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors

Download (20.79 MB)
posted on 2023-03-31, 19:29 authored by James T. Lynch, Urszula M. Polanska, Oona Delpuech, Urs Hancox, Antonio G. Trinidad, Filippos Michopoulos, Carol Lenaghan, Robert McEwen, James Bradford, Radek Polanski, Rebecca Ellston, Alvaro Avivar-Valderas, James Pilling, Anna Staniszewska, Marie Cumberbatch, Susan E. Critchlow, Francisco Cruzalegui, Simon T. Barry

Supplemtary figures 1-9





Purpose: PTEN-null tumors become dependent on the PI3Kβ isoform and can be targeted by molecules such as the selective PI3Kβ inhibitor AZD8186. However, beyond the modulation of the canonical PI3K pathway, the consequences of inhibiting PI3Kβ are poorly defined.Experimental Design: To determine the broader impact of AZD8186 in PTEN-null tumors, we performed a genome-wide RNA-seq analysis of PTEN-null triple-negative breast tumor xenografts treated with AZD8186. Mechanistic consequences of AZD8186 treatment were examined across a number of PTEN-null cell lines and tumor models.Results: AZD8186 treatment resulted in modification of transcript and protein biomarkers associated with cell metabolism. We observed downregulation of cholesterol biosynthesis genes and upregulation of markers associated with metabolic stress. Downregulation of cholesterol biosynthesis proteins, such as HMGCS1, occurred in PTEN-null cell lines and tumor xenografts sensitive to AZD8186. Therapeutic inhibition of PI3Kβ also upregulated PDHK4 and increased PDH phosphorylation, indicative of reduced carbon flux into the TCA cycle. Consistent with this, metabolomic analysis revealed a number of changes in key carbon pathways, nucleotide, and amino acid biosynthesis.Conclusions: This study identifies novel mechanistic biomarkers of PI3Kβ inhibition in PTEN-null tumors supporting the concept that targeting PI3Kβ may exploit a metabolic dependency that contributes to therapeutic benefit in inducing cell stress. Considering these additional pathways will guide biomarker and combination strategies for this class of agents. Clin Cancer Res; 23(24); 7584–95. ©2017 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager